You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

EGFR Mutant

Showing 1 - 25 of 2,301
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Radiotherapy Combined With EGFR-TKI for Stage III EGFR Mutant

Completed
  • The Primary Study Metric is Progression-free Survival (PFS)
    • (no location specified)
    Jun 28, 2023

    Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC

    Recruiting
    • Non-small Cell Lung Cancer
      • Guanzhou, China
        Sun Yat-sen University Cancer Center
      Aug 11, 2023

      NSCLC, Epidermal Growth Factor Receptor, Leptomeningeal Metastasis Trial (Pemetrexed)

      Not yet recruiting
      • Carcinoma, Non-Small-Cell Lung
      • +2 more
      • (no location specified)
      Mar 27, 2023

      NSCLC Metastatic Trial in Seoul (Lazertinib, Tepotinib)

      Not yet recruiting
      • Non-Small Cell Lung Cancer Metastatic
      • Seoul, Gangnam-gu, Korea, Republic of
        Samsung Medical Center
      Oct 27, 2023

      Lung Cancer Trial in Guangzhou (Aumolertinib)

      Not yet recruiting
      • Lung Cancer
      • Guangzhou, Guangdong, China
        The First Affiliated Hospital of Guangzhou Medical University
      Jul 7, 2023

      Non Small Cell Lung Cancer Trial in Seoul (Lazertinib+Pemetrexed+Carboplatin, Lazertinib)

      Not yet recruiting
      • Non Small Cell Lung Cancer
      • Seoul, Korea, Republic of
        Yonsei University Health System, Severance Hospital
      Aug 31, 2023

      NSCLC Trial in Singapore (Oral S-1 + Oral Osimertinib)

      Not yet recruiting
      • NSCLC
      • Oral S-1 + Oral Osimertinib
      • Singapore, Singapore
        National Cancer Center Singapore
      Mar 6, 2023

      Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in

      Not yet recruiting
      • Metastatic Lung Non-Small Cell Carcinoma
      • +2 more
      • Cetuximab
      • +2 more
      • Sacramento, California
        University of California Davis Comprehensive Cancer Center
      Oct 2, 2023

      EGFR Mutation-Related Tumors Trial (NX-019)

      Not yet recruiting
      • EGFR Mutation-Related Tumors
      • (no location specified)
      Aug 22, 2022

      IASLC Grading System as a Predictor for EGFR-TKI Therapy

      Completed
      • Lung Cancer
      • IASLC grading system
      • Shanghai, Please Select, China
        Chaoqiang Deng
      Nov 9, 2023

      NSCLC Trial (Almonertinib Envafolimab)

      Not yet recruiting
      • Non-small Cell Lung Cancer
      • Almonertinib Envafolimab
      • (no location specified)
      Sep 10, 2022

      EGF-R Positive NSCLC, Non Small Cell Lung Cancer, EGFR Exon 19 Deletion Trial in Bogotá (Stereotactic Body Radiation Therapy

      Not yet recruiting
      • EGF-R Positive Non-Small Cell Lung Cancer
      • +4 more
      • Stereotactic Body Radiation Therapy SBRT
      • Bogotá, Colombia
        CTIC - Centro de Tratamiento e Investigación Sobre Cáncer Luis C
      Aug 16, 2023

      NSCLC Trial in Boston (Osimertinib)

      Recruiting
      • Carcinoma, Non-Small-Cell Lung
      • Boston, Massachusetts
      • +1 more
      Sep 28, 2022

      EGFR Mutant Advanced NSCLC Trial (JIN-A02)

      Not yet recruiting
      • EGFR Mutant Advanced Non-small Cell Lung Cancer
      • (no location specified)
      Jul 8, 2022

      Lung Cancer Metastatic, EGFR Gene Mutation Trial in San Francisco (Osimertinib, Alisertib)

      Recruiting
      • Lung Cancer Metastatic
      • EGFR Gene Mutation
      • San Francisco, California
        University of California, San Francisco
      Aug 10, 2022

      NSCLC, EGFR Activating Mutation Trial in Guangzhou (Sintilimab, Carboplatin, Nab paclitaxel)

      Recruiting
      • Non-small Cell Lung Cancer
      • EGFR Activating Mutation
      • Sintilimab
      • +2 more
      • Guangzhou, Guangdong, China
        Guangdong Lung Cancer Institute, Guangdong Provincial People's H
      Aug 8, 2022

      EGFR-mutant NSCLC Trial in Worldwide (EGF816, trametinib, ribociclib)

      Active, not recruiting
      • EGFR-mutant Non-small Cell Lung Cancer
      • Toronto, Ontario, Canada
      • +10 more
      Dec 5, 2022

      EGFR Mutant Advanced NSCLC Trial (BBT-207)

      Not yet recruiting
      • EGFR Mutant Advanced Non-Small Cell Lung Cancer
      • (no location specified)
      Jun 16, 2023

      EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

      Recruiting
      • Non-small Cell Lung Cancer
        • Changsha, Hunan, China
          Yongchang Zhang
        Feb 28, 2022

        Non-Small-Cell Lung Cancer Trial in Shanghai (Furmonertinib (160mg))

        Recruiting
        • Non-Small-Cell Lung Cancer
        • Furmonertinib (160mg)
        • Shanghai, Shanghai, China
          Fudan University Shanghai Cancer Center
        Aug 2, 2022

        Non Small Cell Lung Cancer Trial in Italy (Osimertinib)

        Recruiting
        • Non Small Cell Lung Cancer
        • Ancona, Italy
        • +10 more
        Mar 14, 2023

        NSCLC Trial (SKB264, Pemetrexed, Carboplatin)

        Not yet recruiting
        • Non-small Cell Lung Cancer
        • (no location specified)
        May 23, 2023

        NSCLC Trial (PM8002, Placebo, Carboplatin)

        Not yet recruiting
        • NSCLC
        • (no location specified)
        Feb 23, 2023

        NSCLC Trial in Boston, Durham (Osimertinib, Selumetinib)

        Active, not recruiting
        • Non-small Cell Lung Cancer
        • Boston, Massachusetts
        • +3 more
        Aug 1, 2022

        EGFR, NSCLC, Third-generation TKI Trial (Almonertinib and metronomic oral vinorelbine)

        Not yet recruiting
        • EGFR
        • +2 more
        • Almonertinib and metronomic oral vinorelbine
        • (no location specified)
        Dec 21, 2022